Article

Tear osmolarity test gets CLIA waiver

TearLab Corp. announced that its proprietary tear osmolarity analysis test (TearLab Osmolarity System) has been granted FDA waiver categorization under the Clinical Laboratory Improvement Amendments of 1988.

San Diego-TearLab Corp. announced that its proprietary tear osmolarity analysis test (TearLab Osmolarity System) has been granted FDA waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

“We believe that with CLIA waiver and Medicare reimbursement in place, and with the updated American Academy of Ophthalmology's Preferred Practice Pattern guidelines listing tear osmolarity as a more sensitive method to diagnose dry eye disease, [the proprietary test] is now well on its way toward being established as a standard of care,” said Elias Vamvakas, TearLab's chief executive officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
© 2025 MJH Life Sciences

All rights reserved.